

DAICEL provides Immunetune with "Actranza™ lab. technology" for their development of next generation DNA vaccines against cancer and infection diseases

Daicel Co., Ltd. (Chief: Kita-ku, Osaka, President: Yoshimi Ogawa, hereinafter "Daicel") provides our drug delivery device, "Actranza™ lab" to Immunetune (CEO: Leiden, The Netherlands, CEO Sijme Zeilemaker, hereinafter "Immunetune") for their development of next-generation DNA vaccines for cancer and infection diseases.

In pharmacological studies using animal models conducted by Immunetune, improvements in immunogenicity by "Actranza™ lab" were observed when compared with normal needle injection. In response to this result, DAICEL and Immunetune have decided to continue the joint evaluation with the aim of using our device for pre-clinical and further clinical trials of Immunetune's next-generation DNA vaccine.

<Participation of DAICEL>

DAICEL develops a gene transfer method by using the Actranza™ lab. technology and is conducting research for its clinical application. The Actranza™ lab. technology enables gene transfer along with good intradermal delivery, leading to efficient vaccination.

<Overview of the drug delivery device Actranza™ lab>

This technology distributes a liquid into a specific organ with a needle-free system by using a force generated from an energy control technology called "One Time Energy™ DAISI". According to the results of the animal studies, a higher gene expression is achieved upon accurate delivery to skin (the dermis/epidermis layer) than the conventional needle injection. Since dermal/epidermal tissue contains more immunocompetent cells than the muscle tissue, the efficacy of the vaccines can be enhanced when vaccine is delivered in this mode.

* About "Actranza™ Lab": https://www.daicel.com/safety/daisi/actranza_pr/

* About One Time Energy™ DAISI: <https://www.daicel.com/safety/daisi/>

About Immunetune

Immunetune is a preclinical-stage biotech developing next-generation DNA vaccines against

cancer and infectious diseases. Its proprietary set of technologies allow the rapid, cell-free production of personalized cancer vaccines encoding multiple (neo-)antigens in synthetic, linear DNA with improved immunogenicity through its unique PyroVant™ adjuvant. Its lead cancer vaccine has achieved preclinical Proof of Concept in animal studies and has completed GLP toxicity studies, with the aim to initiate clinical studies in 2022. Immunetune's pipeline further consists of infectious disease vaccines, including a pan-corona DNA vaccine, targeting antigens conserved across multiple strains of coronaviruses for global pandemic readiness, currently in preclinical testing.

www.immunetune.com

About Daicel

DAICEL is a diversified chemical company with business operations in Japan and around the world. Under the basic philosophy of "the company making lives better by co-creating value." Daicel provides materials that benefit society and people in a wide range of business fields with the keywords of "health," "safety and security," "convenience and comfort," and "environment". Through Mid-term Management strategy, we will focus on the creation of new biomass product trees using renewable resources such as forest resources and the development of innovative process technologies to realize them in an environmentally friendly manner, utilizing the plant-derived cellulose technology that we have been dealing with since our establishment, to create a recycling-oriented society that leads to carbon neutrality. For more information about Daicel, please visit <https://www.daicel.com/en/>.